

Available Technologies

Contact Us

Request Information

Glycoengineering Of The Foldon Protein Trimerization Domain To Shield It From Antibody Immune Responses

Tech ID: 32956 / UC Case 2021-990-0

BACKGROUND

Vaccine design is at the forefront of therapeutic development. Candidate proteins for recombinant vaccine design are expressed as soluble proteins lacking the native transmembrane domain. These proteins are often fused with multimerization domains to stabilize the native oligomeric state of the candidate protein. However, these multimerization domains can elicit off-target immune responses, raising concerns regarding risks of unintended immunogenicity. Thus, there is a need to eliminate potential off-target effects of recombinant vaccine candidates that contain multimerization domains such as the foldon domain.

TECHNOLOGY DESCRIPTION

To address this, researchers at UC Santa Cruz have developed glycoengineered foldon domains to include N-linked glycosylation motifs. Foldon domains that are glycosylated may produce a lower immune response than foldon domains that are not glycosylated, when administered to a subject.

APPLICATIONS

- vaccine design
- recombinant protein vaccines
- multimeric vaccine antigens
- ▶ trimeric vaccine antigens
- ▶ immunosilencing

ADVANTAGES

- reduces foldon immunogenicity
- eliminates off-target effects in recombinant vaccine candidates

INTELLECTUAL PROPERTY INFORMATION

| Country | Туре | Number | Dated | Case |
|------------------------|-----------------------|---------|------------|----------|
| European Patent Office | Published Application | 4380960 | 06/12/2024 | 2021-990 |

Additional Patent Pending

RELATED MATERIALS

> Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine -

04/25/2023



INVENTORS

DuBois, Rebecca M.

Dzimianski, John

OTHER INFORMATION

KEYWORDS vaccine design, recombinant protein vaccines, foldon, immunosilencing, glycoengineering, glycosylation

CATEGORIZED AS

Biotechnology

Health

- Medical
 - Disease: Infectious
 - Diseases

Vaccines

RELATED CASES 2021-990-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- Human Astrovirus Neutralizing Monoclonal Antibody Sequences
- Simplified Workflow For Hybridoma Antibody Sequencing
- Methods To Rapidly Measure Antibodies And Other Biomolecules In Clinical Specimens Utilizing Biolayer Interferometry

University of California, Santa Cruz

Tel: 831.459.5415

Industry Alliances & Technology Commercialization Kerr 413 / IATC,

Santa Cruz,CA 95064

https://officeofresearch.ucsc.edu/ Fax: 831.459.1658

innovation@ucsc.edu

© 2022 - 2024, The Regents of the University of California Terms of use

Privacy Notice